← Leaderboards
Ricardo Valladares
Siolta Therapeutics, Inc.
$3,750,630
Attributed
$3,750,630
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,750,630 · 3
By mechanism
R44$3,450,630 · 2
R43$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Clinical Development”
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Mari Ostendorf · University Of Washington$51,931,230
- Brian Zavertnik · Palantir Technologies, Inc.$33,059,912
- Joan Grand · Mitre Corporation$32,826,287
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Lauren Miller · Technical Resources International, Inc.$31,120,905
Research focus
Clinical DevelopmentBacteriaBiological Response Modifier TherapyDesignPreventFormulationMemberLactobacillusProcess OptimizationCellsTherapeutic CandidatePharmacologic SubstancePreventionProbioticsMicrobialIn VivoMorbidity - Disease RateGut MicrobiotaImmuneClinical TrialsEvaluationInfantPharmaceutical PreparationsUpdate
Grant awards (5)
Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis$529,498
R44 · FY2025 · AI · contact PI
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products$948,833
R44 · FY2024 · AI · contact PI
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products$993,238
R44 · FY2023 · AI · contact PI
A Synergistic Multistrain Live Biotherapeutic Product for the Prevention and Treatment of Necrotizing Enterocolitis$300,000
R43 · FY2023 · AI · contact PI
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products$979,061
R44 · FY2022 · AI · contact PI